Healthy donor cells tell you how a normal immune system behaves. Autoimmune disease is a question about how an abnormal one behaves, and a substantial amount of published work answers it with healthy cells plus a stimulus, which is a model of activation rather than a model of disease.
What disease-state material carries that healthy material cannot
Cells from a patient with an autoimmune condition arrive having been shaped by the disease. The memory compartment reflects the actual antigenic history. Regulatory populations may be altered in frequency or function. Activation states differ at baseline. Treatment history has left its own imprint.
None of that can be recreated by stimulating healthy cells, because the stimulus produces an acute response rather than the chronic remodelled state that characterises established disease.
What has to travel with the cells
| Attribute | Why it is not optional |
|---|---|
| Confirmed diagnosis | Self-reported diagnosis is not a cohort definition |
| Disease activity | Active and quiescent disease produce different cells |
| Treatment status | Immunomodulatory therapy reshapes exactly what you are measuring |
| Time since diagnosis | Early and established disease differ |
| HLA genotype | Several autoimmune conditions carry strong HLA associations |
| Matched healthy controls | A disease cohort without a comparator is descriptive rather than analytical |
Treatment status deserves particular emphasis. A patient on immunomodulatory therapy provides cells that reflect the disease and the drug together, and separating those afterwards is usually impossible. Whether that is acceptable depends entirely on the question, and it should be a stated inclusion criterion rather than a discovery.
Related product
Disease-state PBMCs. PBMCs from donors with a documented diagnosis, across 24 autoimmune and inflammatory indications.
The HLA connection
Some of the strongest genotype associations in human disease sit in the HLA region, including HLA-B*27 with ankylosing spondylitis, HLA-DQ2 and DQ8 with celiac disease, and HLA-DR3 and DR4 with type 1 diabetes. For research purposes this means a disease cohort can be stratified by genotype rather than by diagnosis alone, which frequently produces a cleaner comparison. The background is in the HLA system.
Matched components matter more here than elsewhere
Serum and plasma from the same donor as the cells allow autoantibody and soluble factor measurements to be tied to the cellular phenotype from that individual. Requested at the point of collection this is straightforward. Requested afterwards it is frequently impossible, because the donor has moved on and the material was not retained.
Specification differs from healthy-donor material
Disease-state material carries its own specifications and should not be assumed to match the healthy-donor equivalents. OrganaBio documents disease-state material for research use with a viability specification of greater than 80% post-thaw, which is deliberately distinct from healthy-donor figures, across 24 autoimmune indications covering discovery, drug screening and biomarker work.
The catalogue includes disease-state PBMCs across several indications alongside matched serum and plasma for lupus donors. Broader sourcing considerations are in buying human biospecimens.
Why the field is moving
B cell depletion producing durable remission in refractory autoimmune disease has redirected a considerable amount of research attention toward the B cell compartment in these conditions, and toward the question of whether depletion resets an autoreactive compartment rather than merely suppressing it. That work needs patient-derived cells rather than healthy proxies, which is a large part of why demand for characterized disease-state material has risen. The B cell side is covered in CD19+ B cells.
Frequently asked questions
Why use disease-state donor material instead of stimulated healthy cells?
Because stimulation produces an acute activation response rather than the chronic remodelled state of established disease. Patient cells carry a memory compartment shaped by real antigenic history, altered regulatory populations, different baseline activation and the imprint of treatment.
What information must accompany disease-state cells?
Confirmed rather than self-reported diagnosis, disease activity, treatment status, time since diagnosis, HLA genotype where relevant, and access to matched healthy controls. Without those a disease cohort is descriptive rather than analytical.
Why does treatment status matter so much?
A patient on immunomodulatory therapy provides cells reflecting both the disease and the drug, and separating those afterwards is usually impossible. It should be a stated inclusion criterion rather than something discovered during analysis.
Should autoimmune cohorts be stratified by HLA genotype?
Frequently yes. Several autoimmune conditions carry strong HLA associations, and stratifying by genotype rather than by diagnosis alone often produces a cleaner comparison than diagnosis provides on its own.
Why request matched serum and plasma at the outset?
Because they allow autoantibody and soluble factor measurements to be tied to the cellular phenotype from the same individual. Requested at collection this is straightforward; requested later it is often impossible because the material was not retained.
Do disease-state products carry the same specifications as healthy donor material?
No, and assuming so is a common error. OrganaBio documents disease-state material with a viability specification of greater than 80% post-thaw, deliberately distinct from healthy-donor figures.
Why has demand for autoimmune donor material increased?
Largely because B cell depletion has produced durable remission in refractory autoimmune disease, redirecting research toward the B cell compartment and toward whether depletion resets an autoreactive compartment. That work requires patient-derived cells rather than healthy proxies.
Talk to OrganaBio
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
